JP2008523061A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523061A5
JP2008523061A5 JP2007545497A JP2007545497A JP2008523061A5 JP 2008523061 A5 JP2008523061 A5 JP 2008523061A5 JP 2007545497 A JP2007545497 A JP 2007545497A JP 2007545497 A JP2007545497 A JP 2007545497A JP 2008523061 A5 JP2008523061 A5 JP 2008523061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
interleukin
interferon
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007545497A
Other languages
English (en)
Japanese (ja)
Other versions
JP5704788B2 (ja
JP2008523061A (ja
Filing date
Publication date
Priority claimed from US11/261,931 external-priority patent/US7964571B2/en
Application filed filed Critical
Publication of JP2008523061A publication Critical patent/JP2008523061A/ja
Publication of JP2008523061A5 publication Critical patent/JP2008523061A5/ja
Application granted granted Critical
Publication of JP5704788B2 publication Critical patent/JP5704788B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007545497A 2004-12-09 2005-11-17 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ Expired - Fee Related JP5704788B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63504204P 2004-12-09 2004-12-09
US60/635,042 2004-12-09
US11/261,931 US7964571B2 (en) 2004-12-09 2005-10-28 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US11/261,931 2005-10-28
PCT/US2005/041935 WO2006062723A2 (en) 2004-12-09 2005-11-17 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012105614A Division JP2012188430A (ja) 2004-12-09 2012-05-07 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ

Publications (3)

Publication Number Publication Date
JP2008523061A JP2008523061A (ja) 2008-07-03
JP2008523061A5 true JP2008523061A5 (enExample) 2009-01-15
JP5704788B2 JP5704788B2 (ja) 2015-04-22

Family

ID=36578384

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007545497A Expired - Fee Related JP5704788B2 (ja) 2004-12-09 2005-11-17 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2012105614A Pending JP2012188430A (ja) 2004-12-09 2012-05-07 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2014092250A Pending JP2014169305A (ja) 2004-12-09 2014-04-28 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012105614A Pending JP2012188430A (ja) 2004-12-09 2012-05-07 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2014092250A Pending JP2014169305A (ja) 2004-12-09 2014-04-28 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ

Country Status (9)

Country Link
US (3) US7964571B2 (enExample)
EP (2) EP2444498A1 (enExample)
JP (3) JP5704788B2 (enExample)
CN (1) CN101111154B (enExample)
AT (1) ATE540121T1 (enExample)
AU (1) AU2005314468B2 (enExample)
CA (1) CA2590160C (enExample)
ES (1) ES2380107T3 (enExample)
WO (1) WO2006062723A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
PT2730277T (pt) 2004-12-22 2020-04-21 Nitto Denko Corp Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP5279235B2 (ja) * 2007-11-05 2013-09-04 国立大学法人 岡山大学 抗癌剤耐性癌において抗癌剤増強作用を有する癌細胞死誘導剤
US20100056475A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Cyclodextrin conjugates
CA2759098A1 (en) * 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
JP2013522375A (ja) * 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CN102784398B (zh) * 2011-05-16 2014-06-18 南京大学 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
WO2012155328A1 (zh) * 2011-05-16 2012-11-22 南京大学 包含内皮抑素和rna干扰分子的组合物及其应用
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
JP5904483B2 (ja) * 2011-09-06 2016-04-13 国立大学法人 長崎大学 研磨剤を含有する核酸導入剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014063128A1 (en) * 2012-10-20 2014-04-24 Board Of Regents, The University Of Texas System Cancer cell trap
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
ITMI20122270A1 (it) * 2012-12-31 2014-07-01 Giovanni Mogna Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie.
HK1217215A1 (zh) 2013-01-17 2016-12-30 Modernatx, Inc. 用於改变细胞表型的信号传感器多核苷酸
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN105705143A (zh) * 2013-11-08 2016-06-22 达娜-法勃肿瘤研究所公司 用于体内试剂递送的核酸纳米结构
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3206987B2 (en) 2014-10-14 2024-07-24 The University of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3426598B1 (en) 2016-03-11 2021-07-28 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
CN109561691A (zh) * 2016-06-07 2019-04-02 太平洋心肺血研究所 用于治疗癌症的组合物和方法
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN115948505B (zh) 2016-08-02 2025-07-25 哈佛学院院长及董事 交叉协同自组装体
WO2018048792A1 (en) 2016-09-08 2018-03-15 North Carolina State University Methods for diagnosis of pseudoperonospora cubensis infection and selection of plant resistance genes to the same
JP6850870B2 (ja) * 2017-03-31 2021-03-31 富士フイルム株式会社 圧電体膜、圧電素子、及び、圧電素子の製造方法
WO2018232502A1 (en) * 2017-06-20 2018-12-27 Rjh Biosciences Inc. Transfection reagents for delivery of nucleic acids
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CA3111100A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US12268748B2 (en) 2019-04-10 2025-04-08 President And Fellows Of Harvard College Nucleic acid nanostructures crosslinked with oligolysine
TWI870475B (zh) * 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料
US20240180849A1 (en) * 2021-04-20 2024-06-06 Purdue Research Foundation Immunofunctional carrier, methods of uses, and composition matters as an antitumor immunotherapy
CN116621965A (zh) * 2022-05-06 2023-08-22 珠海丽凡达生物技术有限公司 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
JP2025532514A (ja) * 2022-09-07 2025-10-01 イムノン、インコーポレイテッド 癌を治療するためのｉｌ－１２遺伝子治療と抗ｖｅｇｆとの併用
CN117144509A (zh) * 2023-02-21 2023-12-01 山东第一医科大学(山东省医学科学院) 一种乳腺癌联合治疗的Bcl-2 siRNA@DOX核/壳纤维材料及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4121982A (en) 1978-02-03 1978-10-24 American Chemical & Refining Company Incorporated Gold alloy plating bath and method
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
JP3078107B2 (ja) 1992-04-07 2000-08-21 日本原子力研究所 放射性廃棄物の減容処理方法
JP3347381B2 (ja) 1993-01-27 2002-11-20 協和醗酵工業株式会社 ペットフード
US5393335A (en) 1993-04-23 1995-02-28 Ppg Industries, Inc. Starch-oil sizing for glass fibers
AU4690596A (en) 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6410046B1 (en) 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
US5955415A (en) 1997-08-04 1999-09-21 Lever Brothers Company, Division Of Conopco, Inc. Detergent compositions containing polyethyleneimines for enhanced peroxygen bleach stability
IL139761A0 (en) 1998-05-20 2002-02-10 Expression Genetics Inc A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier
CN101041079A (zh) 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
AU6814601A (en) * 2000-06-01 2001-12-11 Sloan Kettering Inst Cancer Use of mutant herpes viruses and anticancer agents in the treatment of cancer
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
JP2004510829A (ja) 2000-10-09 2004-04-08 バイエル　アクチェンゲゼルシャフト 核酸を細胞内に転移させるための複合体
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
JP2006517790A (ja) 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション ポリペプチド−核酸複合体の細胞の送達および活性化
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US7740880B2 (en) 2006-03-03 2010-06-22 University Of Utah Research Foundation Polymeric carrier for delivery of small interfering RNA

Similar Documents

Publication Publication Date Title
JP2008523061A5 (enExample)
CA2590160C (en) Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
Stecanella et al. Glycyrrhizic acid and its hydrolyzed metabolite 18β-glycyrrhetinic acid as specific ligands for targeting nanosystems in the treatment of liver cancer
Daniels et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Akkın et al. A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers
Yadav et al. Advances in delivery of chemotherapeutic agents for cancer treatment
Luiz et al. Targeted liposomes: A nonviral gene delivery system for cancer therapy
US20240108750A1 (en) Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
Son et al. Carbon nanotubes as cancer therapeutic carriers and mediators
Johnson et al. Surface-engineered extracellular vesicles in cancer immunotherapy
He et al. Functionalized nanoparticles targeting tumor-associated macrophages as cancer therapy
Huwyler et al. Tumor targeting using liposomal antineoplastic drugs
Schätzlein Targeting of synthetic gene delivery systems
JP2009114191A5 (enExample)
Zocchi et al. Cancer nanomedicine special issue review anticancer drug delivery with nanoparticles: Extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy
CN102203002A (zh) 纳米治疗性胶态金属组合物和方法
Tracey et al. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface
Lin et al. An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer
Vieira Gonzaga et al. Targeting groups employed in selective dendrons and dendrimers
WO2017123627A1 (en) Bispecific targeting agents and methods for their preparation
Kubbara et al. Advances in Liposomal Interleukin and Liposomal Interleukin Gene Therapy for Cancer: A Comprehensive Review of Preclinical Studies
Sharma et al. A pioneer review on lactoferrin as versatile macromolecular ligand for targeting cancer: recent advances
Shurygina et al. Use of Nanoselenium in Chemotherapy Drug Delivery Systems
Prazeres et al. Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches
Ren et al. Research Progress on Polymer-Based Nanocarriers for Tumor-Targeted Delivery of Survivin siRNA